Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET for osseointegration and bone remodelling; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid with anti-inflammatory properties that promotes the effect of active components, as well as acts as a cell colonization supporting tissue regeneration. The company was incorporated in 2017 and is headquartered in Jumet, Belgium.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Buy
Sell